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Abstract
OBJECTIVES—To explore the relationship between level and type of comorbidity and 
guideline-concordant care for early-stage breast cancer.
DESIGN—Cross-sectional.
SETTING—National Program of Cancer Registry (NPCR) Breast and Prostate Cancer Patterns of 
Care study, which re-abstracted medical records from 2004 in seven cancer registries.
PARTICIPANTS—Individuals with stage 0–III breast cancer.
MEASUREMENTS—Multicomponent guideline-concordant management was modeled based on 
tumor size, node status, and hormone receptor status, according to consensus guidelines. 
Comorbid conditions and severity were measured using the Adult Comorbidity Evaluation Index 
(ACE-27). Multivariate logistic regression models determined factors associated with guideline-
concordant care and included overall ACE-27 scores and 26 separate ACE comorbidity categories, 
age, race, stage, and source of payment.
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RESULTS—The study sample included 6,439 women (mean age 58.7, range 20–99; 76% white; 
44% with no comorbidity; 70% estrogen- or progesterone-receptor positive, or both; 31% human 
epidermal growth factor receptor 2 positive). Care was guideline concordant in 60%. Guideline 
concordance varied according to overall comorbidity burden (70% for none; 61% for minor; 58% 
for moderate, 43% for severe; P < .05). In multivariate analysis, the presence of hypertension 
(odds ratio (OR) = 1.15, 95% confidence interval (CI) = 1.01–1.30) predicted guideline 
concordance, whereas dementia (OR = 0.45, 95% CI = 0.24–0.82) predicted lack of guideline 
concordance. Older age (≥50) and black race were associated with less guideline concordance, 
regardless of comorbidity level.
CONCLUSION—When reporting survival outcomes in individuals with breast cancer with 
comorbidity, adherence to care guidelines should be among the covariates.
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In individuals with breast cancer, comorbidity is linked to lower overall and disease-specific 
survival.1,2 This association may be through effects on disease biology, receipt of or 
response to treatment, or to other factors. Treatment of breast cancer requires 
multicomponent care, including surgery, radiation therapy (RT), endocrine therapy (ET), and 
chemotherapy (CTX). With adjuvant CTX,3,4 toxicity is a concern.5 Adjuvant RT after 
breast-conserving surgery (BCS) is less often used in the presence of comorbidity.6 Certain 
comorbidities may also have different effects on survival, disease course, and treatment.1,7 
Prior studies examining the relationship between guideline care and comorbidity did not 
study dose-response or specific comorbidities.1,3,8,9 The use of the Adult Comorbidity 
Evaluation Index (ACE-27), which includes 26 comorbidities and disease severity, adds 
breadth and power to the analysis.10
Decades of clinical research led to multidisciplinary guidelines that minimize recurrence and 
extend survival in women with breast cancer,11,12 but guidelines do not account for 
comorbidity, and the relationship between guideline concordance and comorbidity is 
understudied. The authors of the current study are aware of only one report of 
multidisciplinary care, which used the Charlson Comorbidity Index derived from 
administrative data.13 Furthermore, it is important to try to disentangle the independent 
effects of age and comorbidity and not just assume that it is morbidity burden in elderly 
adults that effects concordance. This study aimed to examine the relationship between 
comorbidity, with attention to overall burden and specific comorbid conditions, and receipt 
of multicomponent guideline-concordant care. It was hypothesized that age and comorbidity 
burden would have independent effects on guideline concordance.
METHODS
Data Source
The National Program of Cancer Registry (NPCR) Breast and Prostate Cancer Data Quality 
and Patterns of Care Study (POC-BP) study14,15 included individuals with breast cancer 
diagnosed in 2004 from seven population-based cancer registries (California, Georgia, 
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Kentucky, Louisiana, Minnesota, North Carolina, Wisconsin). Human subjects committee 
approval was obtained from each participating institution. Re-abstraction of hospital and 
physician office records supplemented registry data on initial course of treatment. Additional 
data on adjuvant therapy and comorbidities were obtained from physicians and outpatient 
facilities. Cases were randomly selected across strata of race and ethnicity and state-specific 
factors (e.g., Appalachian vs non-Appalachian region, type of facility, and patient volume of 
the facility) and oversampled for racial and ethnic minorities in some states. Cases from 
Veterans Affairs hospitals and identified solely from death certificates or autopsies were 
excluded.
Study Sample
The initial sample included 9,142 women with breast cancer. Exclusion criteria were 
missing stage (n = 1,601); metastatic cancer (n = 358); missing tumor size, if nodal status 
negative or hormone receptor status missing (n = 94); missing nodal status (n = 185); no 
primary breast tumor (T0, n = 22); and missing hormone receptor status and did not receive 
ET (n = 418). Cases in which RT (n = 105), ET (n = 257), and CTX (n = 218) and breast (n 
= 15) or node (n = 14) surgeries were unknown were also excluded. This excluded 2,703 
women, leaving a final sample of 6,439. Characteristics of included women were different 
from those excluded with regard to payor (more Medicare, less Medicaid), race (more 
blacks, fewer Hispanics) and stage (more Stage 0, fewer Stage 2 and 3).
Hormone receptor (estrogen (ER) and progesterone (PR) status was defined as positive (ER+ 
or PR+, or both), negative (ER− and PR−), or unknown. Human epidermal growth factor 
receptor 2 (HER2) status was defined as positive (3 + according to immunohistochemistry 
(IHC) or amplified using fluorescent in situ hybridization (FISH)), negative (0 or 1 + 
according to IHC or 2 + according to IHC and not amplified using FISH), or unknown, 
although HER2 status was not consistently recorded for early-stage breast cancer cases in 
2004.
Outcomes
The primary outcome was receipt of guideline-concordant care or not. Guideline-concordant 
breast cancer treatment was defined based on tumor size, nodal status, and hormone receptor 
status, similar to previous work.13 For each of 10 categories, National Comprehensive 
Cancer Network16 and St. Gallen Conference17 guidelines were consulted to create 
management requirements, which included components of surgery (BCS or mastectomy), 
adjuvant RT (before, during, or after surgery), lymph node surgery (LN), CTX, and ET. 
Minimum acceptable components of therapy for each group are as follows:
Group A (ductal carcinoma in situ (DCIS)), BCS with RT or mastectomy
Group B (T1a-b N0), BCS with RT and LN or mastectomy and LN
Group C+ (T1cN0, >1 cm, ER with PR+), BCS with RT or mastectomy, LN, ET, and 
CTX if younger than 70
Group C− (T1c N0, ER with PR−), BCS with RT or mastectomy, LN, and CTX
Group D+ (T2N0, ER with PR+), BCS with RT or mastectomy, LN, ET, and CTX
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Group D− (T2N0, ER with PR−), BCS with RT or mastectomy, LN, and CTX
Group E+ (T1–3 N1–3 or T3N0, and ER with PR+), BCS with RT or mastectomy, 
LN, ET, and CTX
Group E− (T1–3N1–3 or T3N0 and ER with PR−), BCS with RT or mastectomy, LN, 
and CTX
Group F+ (T4NX and ER with PR+), mastectomy, LN, ET, and CXT
Group F− (T4NX and ER with PR−), mastectomy, LN, and CTX
Receipt of more than guideline management was considered guideline concordant.
Comorbidity
The ACE-27,10 a robust, validated, chart-based instrument developed specifically for 
individuals with cancer, was used. The index includes 26 conditions relevant to cancer 
therapy choice and outcome, and their severity, measured according to three levels of 
decompensation. After training using a tested and validated Internet-based program, 
abstractors reviewed records and assigned comorbidity categories and level of 
decompensation based on diagnoses, medical history, and laboratory and clinical tests.10,18 
Comorbidities present at or before diagnosis were included; complications of treatment were 
excluded. An overall comorbidity index (none, low, moderate, or severe) was assigned to 
each participant based on the comorbidity with the highest level of decompensation. Severe 
level of decompensation for the overall index was assigned in cases in which there was a 
moderate level of decompensation of two or more comorbidities in different body systems 
(e.g., cardiovascular and nervous), even if none were severe.18
The 26 categories were also mapped into 12 groups, based on organ system: cardiovascular 
disease (myocardial infarction, coronary artery disease, congestive heart failure, arrhythmia, 
hypertension, venous disease, peripheral artery disease), respiratory diseases, gastrointestinal 
diseases (hepatic disease, stomach or intestinal diseases, pancreatic disease), renal disease, 
diabetes mellitus, nervous system (stroke or cerebrovascular accident, dementia, paralysis, 
neuromuscular disorders), psychiatric, rheumatological, acquired immunodeficiency 
syndrome (AIDS), cancer (solid tumor, leukemia, lymphoma) excluding the index cancer, 
substance abuse (alcohol abuse, illicit drugs), morbid obesity.
Statistical Analysis
Cases were stratified according to overall comorbidity burden (none, minor, moderate, 
severe). Receipt of guideline-concordant breast cancer care, for each group across the 
aggregated and disaggregated measures of burden, was compared using chi-square statistics. 
Similar analyses were conducted for each of the 12 mapped comorbidity categories (as 
above). Finally, multivariate logistic regressions were estimated using three comorbidity 
classifications: 26 ACE-27 comorbidity categories (Model 1), 12 collapsed ACE-27 
categories (Model 2), and four levels of comorbidity (Model 3). Three models were created 
to maximally explore specific comorbidities and groups of comorbidities and to study the 
dose-response relationship overall. With these regressions, the statistics are reported for four 
age categories (<50, 50–64, 65–74, ≥75) and four racial ethnic groups (white, black, 
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Hispanic, other), because these are factors known to be related to comorbidity and to 
guideline concordance and control for the 10 stage groups and source of payment. SAS 
version 9.2 was used throughout the analyses (SAS Institute, Inc., Cary, NC).
RESULTS
The study population was primarily Caucasian (76.0%), with mean age of 58.7 (range 20–
99; Table 1). ACE comorbidity level was severe in 3.9%, moderate in 9.9%, mild in 42.0%, 
and none in 44.3%. The most common comorbidities were cardiovascular disease (n = 
2,952, 45.8%), diabetes mellitus (n = 802, 12.5%), morbid obesity (n = 534, 8.3%), 
psychiatric disease (n = 381, 5.9%), and respiratory disease (n = 380, 5.9%).
Care was guideline concordant in two-thirds of participants (69.5% without comorbidity, 
59.5% with). Surgery was BCS in 57.9% and mastectomy in 40.9%; 82.7% had had a LN 
assessment. RT occurred in 80.6% of participants who underwent BCS. CTX was delivered 
to 38.9%. ET was used in 54.7% overall and in 71% of women with ER+ or PR+ tumors or 
both.
Table 2 shows the unadjusted rate of guideline-concordant care according to stage and 
comorbidity categories. Guideline concordance varied between stage groups (unreported 
chi-square P < .001), and level of comorbidity (P < .05). Concordance was inversely 
proportional to comorbidity burden: 69.5% for none, 61.4% for minor, 58.0% for moderate, 
and 42.7% for severe, although this inverse relationship is statistically significant for only 
some individual stage groups (e.g., individuals with DCIS (A)). Table 2 also shows 
statistically significant relationships between individual comorbidity categories and 
guideline-concordant treatment for a number of conditions, including cardiovascular disease, 
end-stage renal disease, diabetes mellitus, nervous system disorders, psychiatric disorders, 
and rheumatological disease. For all but psychiatric disorders, the presence of the condition 
was always associated with less-concordant care. In some cases, such as diabetes mellitus 
and nervous system disorders, there is a clear inverse relationship between severity and 
concordance.
Any comorbidity, versus none, was associated with less-guideline-concordant care (P < .05) 
in four stage strata (stage I, tumor >1 cm and hormone receptor positive (C+), 26.1% vs 
37.7%; stage IIA and hormone receptor positive (D+), 29.5% vs 53.2%; stage IIA and 
hormone receptor negative (D−), 53.1% vs 75%; and stage IIB or III and hormone receptor 
positive (E+), 56.8% vs 67.5%) and overall (59.5% vs 69.5%). The presence of comorbidity 
did not significantly affect the rate of guideline-concordant care for DCIS or less than 1 cm, 
node-negative cancers, for which only local therapy met guideline concordance. Few cases 
of higher-stage cancer may have limited the ability to find significant differences in rates of 
guideline-concordant care according to comorbidity level.
The effect of specific diagnosis and severity on receipt of guideline-concordant care was 
examined (Table 2). In unadjusted analyses, comparing any comorbidity with none, receipt 
of guideline-concordant care was less likely (P < .05) with cardiovascular diseases (58% vs 
69%), renal disease (37% vs 64%), diabetes mellitus (54% vs 65%), nervous system disease 
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(35% vs 65%), and rheumatological disease (49% vs 64%). Delivery of guideline-
concordant care was more likely (univariate P < .05) with psychiatric illness (70% vs 63%). 
In univariate analysis, with comorbidity categorized according to level of severity, 
significant differences in guideline-concordant care (P < .05) were found for diabetes 
mellitus and for cardiovascular, renal, and nervous system diseases. For AIDS, other 
cancers, substance abuse, and obesity, small numbers limited detection of a dose-response 
relationship.
Table 3 shows results of multivariate analyses using three models. In Model 1, less guideline 
concordance was associated with dementia (OR = 0.45, 95% CI = 0.24–0.83), older age, and 
black race (vs white OR = 0.87, 95% CI = 0.76–0.99) and higher likelihood of guideline 
concordance with hypertension (OR = 1.15, 95% CI = 1.01–1.30). In Model 2, less guideline 
concordance was associated with renal system disease (OR = 0.57, 95% CI = 0.33–0.99), 
nervous system disease (OR = 0.62, 95% CI = 0.47–0.82), and older age. In Model 3, less 
guideline concordance was associated with severe comorbidity (OR = 0.67, 95% CI = 0.51–
0.89), older age, and black race.
DISCUSSION
Using this large, retrospective database, with systematically collected, detailed information 
about comorbid diagnoses and tumor registry and record-based information about 
multicomponent breast cancer management, the authors of this study confirmed that higher 
comorbidity is associated with a lower rate of multidisciplinary guideline-concordant care. 
Older age and black race also predicted less guideline concordance.19,20 This adds to the 
literature by exploring the effect of specific comorbid diagnoses on receipt of guideline-
concordant breast cancer care. In unadjusted analyses, guideline concordance was lower 
with cardiovascular, renal, nervous system, and rheumatological diseases and diabetes 
mellitus; this held true in adjusted analyses for renal and nervous system diseases. With 
regard to specific diagnoses, dementia was associated with less-guideline-concordant care 
whereas hypertension was associated with small, but statistically significantly greater 
guideline concordance.
It may be that a diagnosis of hypertension implies more access to health care and, therefore, 
greater likelihood of guideline concordance and better outcomes. Individuals with a 
diagnosis of hypertension are likely to receive antihypertensive medication and are more 
likely to receive guideline-concordant care, either of which might improve outcomes. Thus, 
use of guideline-concordant breast cancer care may have confounded previous reports that 
antihypertensive use improves breast cancer prognosis.7,21–23 Future research studying the 
effects of comorbid diagnoses and their treatment on breast cancer outcome should include 
an assessment of guideline-concordant cancer treatment.
In general, higher comorbidity burden led to less guideline-concordant care, which may be 
justified, given the known inverse relationship between comorbidity and life expectancy24 
and higher financial or quality-of-life burdens, especially in those with high comorbidity 
burden. Comorbidity may decrease the benefits or increase the risk of certain components of 
care. For instance, the current study found that individuals with stage IIA disease (T2N0), 
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regardless of hormone receptor status, and stage IIB and III disease with hormone receptor–
positive disease, in which the absolute benefit of adding chemotherapy is small, were 
significantly less likely to receive guideline-concordant care.
Strengths of this study include the large, geographically diverse database, with tumor 
registry data augmented with chart abstraction, and use of the ACE-27 comorbidity measure. 
Record re-abstraction enabled capture of detailed information about tumor characteristics, 
treatment, and comorbid conditions. Whereas most studies of comorbidity were limited to 
older adults with Medicare, this study included individuals aged 20–99. Large sample size 
and availability of well-defined variables pertaining to demographic, participant, tumor, and 
treatment characteristics facilitated study of multicomponent management. Whereas other 
studies have primarily focused on single treatment components, the rich database allowed 
study of multicomponent, coordinated care. Use of the ACE-27, a robust, validated, chart-
based instrument, developed specifically for individuals with cancer to study presence and 
severity of comorbidity, is a tremendous strength of the study.10 Other studies have used 
less-powerful measures of comorbidity.1,3,8,9 The widely used Charlson Comorbidity 
Index25,26 can be used with administrative databases but includes fewer comorbidities and 
no information about disease severity. The Cumulative Illness Rating Scale, perhaps the 
most-comprehensive index, requires detail only available in prospective studies.27 A claims-
based version of the ACE has been proposed.28 Detailed information from the ACE-27 also 
allowed associations with specific comorbid diagnoses, rather than only a summary score of 
comorbidity, to be explored.5
There are limitations to this study. As a retrospective study, what was recorded in the 
medical record, which is a poor source of information about physician and individual 
decision-making, actual referrals, and patient adherence, limited it. Lack of record review 
from each involved physician may have led to missed care components, but the abstractors 
sought records from hospital and physician offices. Inclusion criteria for the analysis 
excluded approximately 25% of the database and may limit external validity of the findings. 
Small numbers in some subcategories limited power. Last, the study was structured to detect 
treatment meeting minimum standards; because less than guideline care is known to be 
associated with worse outcomes, it was felt that overclassification in this direction was 
acceptable.
In summary, this study found that greater comorbidity burden is associated with a lower rate 
of guideline-concordant multidisciplinary care. The noted association between guideline 
care and hypertension is worthy of further study. Because less than guideline-concordant 
care for breast cancer, regardless of age or race, leads to inferior outcomes,29,30 where 
possible in studies of cancer outcome, guideline concordance should be included in 
analyses.
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Table 1
Characteristics of the Sample (N = 6,439)
Characteristic N Weighted Percentage
Age
 <50 1,830 26.7
 50–64 2,419 37.7
 ≥65 2,190 35.6
Race or ethnicity
 White 3,643 76.0
 Black 1,910 15.3
 Hispanic 488 5.2
 Other 396 3.5
Source of payment
 Medicare plus other public insurance 1,432 23.1
 Medicaid 835 9.1
 Private 3,765 61.6
 Not insured or self-pay 177 1.8
 Unknown 230 4.4
Adult Comorbidity Evaluation scorea
 None 2,784 44.3
 Mild 2,729 42.0
 Moderate 654 9.9
 Severe 272 3.9
Stage
 0 1,290 19.9
 I 2,873 47.1
 II 1,773 26.3
 III 503 6.7
Hormone receptor status
 Positive (ER+ or PR+) 4,398 70.0
 Negative (ER− and PR−) 1,470 21.4
 Unknown 571 8.6
HER2 status
 Positive 1,962 30.5
 Negative 2,713 42.1
 Unknown 1,764 27.4
Type of surgery
 BCS 3,645 57.9
 Mastectomy 2,701 40.9
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Characteristic N Weighted Percentage
 None 93 1.2
Lymph node assessment 5,293 82.7
Radiation after BCS 2,967 80.6b
Adjuvant chemotherapy
 Single agents 73 1.1
 Doxorubicin and cyclophosphamide 704 9.9
 Doxorubicin, cyclophosphamide, and a taxane 1,236 18.6
 Other multiple agents 663 9.4
 None 3,765 61.1
Endocrine therapy 3,428 54.7
Trastuzumabc 169 2.9
a
Diseases included myocardial infarction, angina pectoris or coronary artery disease, congestive heart failure, arrhythmias, hypertension, venous 
disease, peripheral arterial disease, respiratory system disease, hepatic disease, stomach or intestinal disease, pancreatic disease, end-stage renal 
disease, diabetes mellitus, stroke, dementia, paralysis, neuromuscular disease, psychiatric disorder, rheumatologic disease, acquired 
immunodeficiency syndrome, solid tumor including melanoma, leukemia or myeloma, lymphoma, alcohol abuse, illicit drugs, obesity.
b
Percent who received adjuvant RT among those who had BCS.
c
Trastuzumab was delivered to 2.9% overall and 8.1% of human epidermal growth factor receptor 2 (HER2)-positive cancers.
ER = Estrogen Receptor; PR = Progesterone Receptor; BCS = Breast-Conserving Surgery.
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Table 3
Multivariate Logistic Regressiona of Guideline-Concordant Care According to Comorbidity, Age, and Race in 
Individuals with Breast Cancer (N = 6,208b)
Comorbidity Group (Model)
Model 1 (Includes Each 
26 Separate ACE-27 
Comorbidity Categories 
in the Model)
Model 2 (Includes 12 
Collapsed ACE-27 
Categories in the 
Model)
Model 3 (Includes 4 
Levels of Comorbidity 
in the Model)
1 (1) 2 (2) Odds Ratio (95% Confidence Interval)
Myocardial infarction 0.94 (0.64–1.37)
Coronary artery disease 0.97 (0.74–1.28)
Congestive heart failure 0.74 (0.52–1.07)
Arrhythmia 0.90 (0.64–1.26)
Hypertension 1.15 (1.01–1.30)c
Venous disease 1.13 (0.67–1.92)
Peripheral arterial disease Cardiovascular 0.67 (0.36–1.22) 1.13 (1.00–1.28)
Respiratory disease Respiratory 1.18 (0.93–1.51) 1.14 (0.89–1.44)
Hepatic disease 0.62 (0.33–1.19)
Stomach or intestinal disease 1.01 (0.68–1.51)
Pancreatic disease Gastrointestinal 0.88 (0.63–1.23)
Renal system disease Renal system disease 0.64 (0.36–1.12) 0.57 (0.33–0.99)c
Diabetes mellitus Diabetes mellitus 0.91 (0.76–1.08) 0.88 (0.75–1.06)
Stroke or cerebrovascular 
accident
0.78 (0.55–1.11)
Dementia 0.45 (0.24–0.83)c
Paralysis 0.88 (0.14–5.66)
Neuromuscular disease Nervous system 0.62 (0.34–1.15) 0.62 (0.47–0.82)c
Psychiatric disease Psychiatric disease 1.28 (1.00–1.63) 1.27 (0.99–1.62)
Rheumatological disease Rheumatological disease 0.79 (0.54–1.15) 0.80 (0.55–1.17)
AIDS AIDS 0.25 (0.04–1.52) 0.25 (0.04–1.53)
Solid tumor 0.54 (0.27–1.09)
Leukemia
Lymphoma Cancer 0.623 (0.328–1.183)
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Comorbidity Group (Model)
Model 1 (Includes Each 
26 Separate ACE-27 
Comorbidity Categories 
in the Model)
Model 2 (Includes 12 
Collapsed ACE-27 
Categories in the 
Model)
Model 3 (Includes 4 
Levels of Comorbidity 
in the Model)
1 (1) 2 (2) Odds Ratio (95% Confidence Interval)
Alcohol abuse 1.006 (0.487–2.077)
Illicit drugs Substance abuse 0.827 (0.296–2.310) 1.021 (0.547–1.904)
Obesity Obesity 1.108 (0.900–1.363) 1.108 (0.901–1.363)
Comorbidity index (vs none)
 Mild 1.124 (0.990–1.277)
 Moderate 1.117 (0.919–1.359)
 Severe 0.673 (0.507–0.893)c
Age (vs <50)
 50–64 0.653 (0.563–0.757)c 0.657 (0.566–0.762)c 0.652 (0.563–0.756)c
 65–74 0.394 (0.325–0.478)c 0.395 (0.326–0.480)‡ 0.385 (0.318–0.465)c
 ≥75 0.135 (0.109–0.167)c 0.131 (0.106–0.162)c 0.126 (0.102–0.155)c
Race (vs white)
 Black 0.872 (0.763–0.996)c 0.878 (0.769–1.002) 0.873 (0.767–0.993)c
 Hispanic 0.924 (0.743–1.149) 0.932 (0.749–1.159) 0.907 (0.730–1.126)
 Other 0.944 (0.741–1.203) 0.949 (0.745–1.208) 0.933 (0.733–1.186)
aControlling for stage and source of payment; pancreatic disease, lymphoma, and leukemia excluded from Model 1 because of too few observations 
(<5).
bObservations excluded (n = 231) for missing payer or race, also omitted metastatic, missing stage, if both PR and ER receptors missing, and if 
tumor size missing and nodes less than N1.
cStatistically significant, three levels of comorbidity and none, chi-square, P < .05.
ACE = Adult Comorbidity Evaluation; AIDS = acquired immunodeficiency syndrome.
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